BG
MRSN

Bellevue Group’s Mersana Therapeutics MRSN Stock Holding History

Bellevue Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-208,745
Closed -$6.63M – 171
2023
Q3 		$6.63M Sell
208,745
-32
-0% -$1.52K 0.11% 96
2023
Q2 		$17.2M Buy
208,777
+36,792
+21% +$5.38M 0.24% 83
2023
Q1 		$17.7M Buy
171,985
+681
+0.4% +$95.6K 0.26% 84
2022
Q4 		$25.1M Buy
171,304
+8,000
+5% +$1.35M 0.33% 77
2022
Q3 		$27.6M Buy
163,304
+7,496
+5% +$1.22M 0.4% 67
2022
Q2 		$18M Sell
155,808
-2,352
-1% -$221K 0.25% 90
2022
Q1 		$15.8M Sell
158,160
-8,400
-5% -$981K 0.18% 98
2021
Q4 		$25.9M Sell
166,560
-3,880
-2% -$755K 0.27% 93
2021
Q3 		$40.2M Buy
170,440
+52,800
+45% +$15.4M 0.41% 78
2021
Q2 		$39.9M Buy
117,640
+3,640
+3% +$1.38M 0.39% 79
2021
Q1 		$46.1M Buy
114,000
+36,960
+48% +$17.9M 0.49% 66
2020
Q4 		$51.3M Buy
+77,040
New +$42.8M 0.59% 52

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bellevue Group's MRSN Position: Q4 2023 in Review

Bellevue Group sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 208,745 shares — an estimated $6.63M sold.

Bellevue Group first reported a position in MRSN in Q4 2020 and held it in 12 quarters. The position peaked at $51.3M in Q4 2020. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

  • Bellevue Group reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Bellevue Group sold 208,745 Mersana Therapeutics shares in Q4 2023, an estimated $6.63M.
  • Bellevue Group first reported a position in Mersana Therapeutics in Q4 2020 and held it in 12 quarters.
  • Bellevue Group's Mersana Therapeutics position peaked at $51.3M in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Bellevue Group's 13F filing for Q4 2023, filed 14 Feb 2024.